Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study Full Text
World Journal of Gastroenterology,  Clinical Article

Tack GJ et al. – The study aims to assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN–PEP) to mitigate the immunogenic effects of gluten in celiac patients. AN–PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN–PEP.

Methods

  • Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included.
  • In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase).
  • After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase).
  • Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology.
  • Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase.
  • Duodenal biopsies were collected after the safety phase and after the efficacy phase.
  • A change in histological evaluation according to the modified Marsh classification was the primary endpoint.

Results

  • In total, 16 adults were enrolled in the study.
  • No serious adverse events occurred during the trial and no patients withdrew during the trial.
  • The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated.
  • In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.
  • During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers.
  • The IgA-EM concentrations remained negative in both groups.
  • Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP.
  • Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.
  • Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.
  • In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Gastroenterology Articles

1 Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms Neurogastroenterology & Motility, February 25, 2014    Clinical Article
Exclusive Author Commentary

2 Use of antibiotics in patients with Crohn's disease: A systematic review and meta-analysis Journal of Digestive Diseases, December 4, 2014    Evidence Based Medicine    Review Article

3 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

4 Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia Digestive Diseases and Sciences, December 12, 2014    Clinical Article

5 Variation in treatment of patients with inflammatory bowel diseases at major US referral centers Clinical Gastroenterology and Hepatology , December 1, 2014    Clinical Article

6 Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn’s disease BioDrugs, December 11, 2014    Review Article

7 Diet and inflammatory bowel disease: review of patient-targeted recommendations Clinical Gastroenterology and Hepatology , October 10, 2014    Review Article

8 Accuracy of rapid fecal calprotectin test in monitoring inflammatory bowel diseases under treatment with TNFα antagonists Digestive Diseases and Sciences, December 9, 2014    Clinical Article

9 Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission Clinical Gastroenterology and Hepatology , December 5, 2014    Clinical Article

10 The results of seton drainage combined with anti-TNF therapy for anal fistula in Crohn's disease Colorectal Disease, December 3, 2014    Clinical Article

11 Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: A meta-analysis of controlled trials Digestive and Liver Diseases, December 8, 2014    Clinical Article

12 The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence following surgery for Crohn's disease Clinical Gastroenterology and Hepatology , November 7, 2014    Clinical Article

13 Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease Full Text Clinical and Experimental Gastroenterology, December 15, 2014    Free full text    Review Article

14 The home environment and childhood obesity in low-income households: indirect effects via sleep duration and screen time Full Text BMC Public Health, November 26, 2014    Free full text    Clinical Article

15 Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterology & Motility, December 3, 2014    Review Article

16 Why, when and how to de-escalate therapy in inflammatory bowel diseases Alimentary Pharmacology and Therapeutics, July 2, 2014    Review Article

17 Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the help randomized clinical trial JAMA Internal Medicine, October 13, 2014    Evidence Based Medicine    Clinical Article

18 Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology, April 2, 2014    Clinical Article

19 Effectiveness of adalimumab in perianal fistulas in Crohn’s disease patients naive to anti-TNF therapy Journal of Clinical Gastroenterology, December 10, 2014    Clinical Article

20 Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity International Journal of Obesity, November 14, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List